A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.
Also called NCT07662213
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,200 participants
- Sponsor
- Registry
-
NCT07662213 -
2025-523933-24-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Germany, Hungary, Italy, Japan, Poland, South Korea, Taiwan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07662213. Randomized; no masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-05-23 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Acronym
- Eluminate-2
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Elecoglipron
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07662213- Content hash
29cd1cb63340f6dcbe9213de779c0f932152cc5ed67b471ad876d4e320cb1a14